Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
(Created page with "=Diseases for which it is used= *Aggressive Non-Hodgkin lymphoma *Mantle cell lymphoma") |
m |
||
| Line 1: | Line 1: | ||
| − | = | + | =Mechanism of action= |
| − | + | Aurora A kinase (AAK) inhibitor | |
| − | + | ||
| + | =Preliminary results= | ||
| + | # Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | ||
| + | |||
| + | [[Category:Investigational]] | ||
| + | [[Category:Kinase inhibitors]] | ||
| + | [[Category:AAK inhibitors]] | ||
| + | |||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
| + | [[Category:Mantle cell lymphoma medications]] | ||
Revision as of 15:50, 16 July 2014
Mechanism of action
Aurora A kinase (AAK) inhibitor
Preliminary results
- Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article PubMed